NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Celularity Inc. (CELU) Stock Analysis

Celularity Inc. (CELU) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

CELU

$1.02

−$0.24 (−19.05%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CELU with… →

CELU Key Statistics

As of Oct 21, 2026
Trading
Open
$1.31
Previous Close
$1.26
Day's Range
1.02–1.31
52-Week Range
0.56–2.55
Volume
204.54K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.78
Valuation
Market Cap
$46.08M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.43
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.73
Financials (FY)
Revenue (FY)
$26.55M−51.03%
Net Income (FY)
−$91.72M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
32.45M
1-Year Return
−49.50%
Dividend and dates
Avg Volume
3.89M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CELU closed at $1.02, −49.50% over 1 year.

Celularity Inc. (CELU) has a market capitalization of $46.08M.

In fiscal 2025, CELU reported revenue of $26.55M.

CELU Stock Return by Calendar Year

Celularity Inc. (CELU) return since Aug 2019: what $10,000 became

1 year
$10,000 $5,050
−49.50%
5 years
$10,000 $146
−98.54%
Since Aug 2019
$10,000 $104
−98.96%

If you had invested $10,000 in Celularity Inc. (CELU) at the close on August 8, 2019, the earliest close on record here, it would have been worth $104 at the close on October 21, 2026: −98.96% in total, −46.94% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−8.11%
2025−46.63%
2024−15.79%
2023−80.85%
2022−74.80%
2021−53.45%
2020+10.55%
2019 (partial year)+1.53%

As of October 21, 2026.

CELU Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$26.55M−$91.72M−345.4%
2024$54.22M−$57.89M−106.8%
2023$22.77M−$196.30M−862.0%
2022$17.98M$14.19M79.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$26.55M$6.48M−$61.31M−$91.72M−345.4%
2024$54.22M$39.23M−$38.55M−$57.89M−106.8%
2023$22.77M$6.76M−$76.48M−$196.30M−862.0%
2022$17.98M−$1.69M−$148.27M$14.19M79.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CELU Valuation vs Biotechnology Median

Median of 608 stocks
MetricCELUBiotechnology medianvs median
P/S ratio2.4313.300.2x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Celularity Inc. (CELU) is capitalised at $46.08M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 115.

The 52-week range on file runs from $0.56 to $2.55. CELU last closed at $1.02 on October 21, 2026. That is −$0.24 (−19.05%) against the previous close. The latest close sits 82.14% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $26.55M. Against the prior fiscal year total of $54.22M, that is a change of −51.03%. The same year closed with a net loss of $91.72M. Trailing earnings per share are −2.73.

Across the 4 fiscal years on file, revenue moves from $17.98M in 2022 to $26.55M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 2.43. On price-to-sales that is 0.2 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is −49.50%. Measured over 5 years, that is −57.09% a year compounded. Beta against the wider market is reported at 0.78. Annualized volatility over the trailing 7 years is 118.75%.

Growth & Income

No dividend is on file for CELU.

2026 is still running; the total return is −8.11% year to date. Across the complete calendar years on file, 2020 returned +10.55% and 2023 returned −80.85%. Of the 6 complete calendar years on file, 1 finished higher.

Peer Comparison

Celularity Inc. (CELU) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Celularity Inc. CELU $46.08M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Celularity Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Celularity Inc.

Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating multiple sclerosis, rheumatoid arthritis, stroke, and diabetic peripheral neuropathy. The company also produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.

Visit website →